Medically Reviewed by Dr. Michael Nguyen, PharmD, BSPharm — Functional Medicine Pharmacist, Sterile Compounding Specialist, PCCA & NHIA Certified. 27+ years of clinical experience in peptide therapy and metabolic health.
Key Takeaways
- › AOD-9604 is a synthetic fragment of human growth hormone (amino acids 176–191) engineered specifically to trigger fat metabolism — without raising IGF-1 or blood glucose.
- › It directly stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat storage), making it uniquely targeted compared to GLP-1 agonists or full hGH therapy.
- › Preclinical studies in obese rodent models show significant visceral and total body fat reduction with consistent dosing.
- › Human clinical trials conducted by Metabolic Pharmaceuticals demonstrated modest but measurable fat loss with a favorable safety profile over 12 weeks.
- › AOD-9604 carries FDA GRAS (Generally Recognized As Safe) status for food-grade use — a rare distinction among peptides.
- › Emerging data suggests secondary benefits for cartilage repair and osteoarthritis, expanding its application beyond fat loss.
- › Best used in a complete metabolic protocol — baseline labs, dietary foundation, and optional stacking with peptides like CJC-1295/Ipamorelin for synergistic effect.
If you’ve been researching peptide therapy for fat loss, you’ve likely come across the usual names — semaglutide, tirzepatide, CJC-1295, Ipamorelin. AOD-9604 tends to fly under the radar by comparison. That’s a mistake.
This peptide fragment does something none of those others do in quite the same way: it goes directly after adipose tissue at the receptor level, mimicking the specific region of human growth hormone responsible for breaking down fat — and it does so without the blood sugar spikes, IGF-1 elevation, or growth-promoting effects that come with actual hGH therapy.
For patients who want targeted fat loss, particularly around visceral fat, without the complexities of full growth hormone protocols, AOD-9604 deserves serious consideration.
Here’s everything you need to know — the science, the clinical data, how it’s used in practice, and what to realistically expect.
[INTERNAL-LINK: What is CJC-1295 Ipamorelin → overview of GHRH/GHRP peptide stacks for body composition]
What Is AOD-9604?
AOD-9604 stands for Anti-Obesity Drug 9604. It’s a synthetic peptide composed of amino acids 176–191 from the C-terminus of human growth hormone (hGH). Researchers at Monash University in Australia, led by Professor Frank Ng, identified this specific region of the hGH molecule as the segment responsible for the hormone’s lipolytic — fat-burning — activity.
Full hGH is a 191-amino-acid protein. The entire molecule has multiple biological effects: it promotes muscle growth, stimulates IGF-1 production in the liver, can raise blood glucose, and influences a wide range of metabolic processes. The fat-burning effect is real with hGH, but it comes bundled with everything else.
AOD-9604 isolates just the last 16 amino acids of that chain — specifically the segment that activates lipolysis — and delivers that action without triggering the growth, IGF-1, or glucose effects of the full molecule.
This is what makes it genuinely novel. You’re not getting a growth hormone secretagogue (like Ipamorelin or Sermorelin), which stimulates your pituitary to release more hGH. You’re getting a fragment that directly acts on fat tissue — bypassing the pituitary axis entirely.
How AOD-9604 Works: The Mechanism
AOD-9604 works through two complementary pathways that together produce meaningful fat loss:
1. Lipolysis Stimulation
AOD-9604 activates lipolysis — the breakdown of stored triglycerides in adipose cells into free fatty acids that can be used for energy. This action appears to be mediated in part through beta-3 adrenergic receptors (β3-AR), which are expressed predominantly on visceral and subcutaneous adipose tissue. Activation of β3-AR increases cyclic AMP (cAMP) within fat cells, triggering hormone-sensitive lipase (HSL) to break down stored fat.
This is the same general pathway targeted by older anti-obesity drugs, but AOD-9604 reaches it via the hGH fragment mechanism rather than through adrenergic agonism broadly — which is why the side effect profile is so much cleaner.
2. Lipogenesis Inhibition
Simultaneously, AOD-9604 inhibits lipogenesis — the creation of new fat from dietary carbohydrates and other substrates. This dual action (break down existing fat + slow new fat formation) is what makes it particularly effective during a caloric deficit. You’re not just burning stored fat — you’re also reducing the rate at which your body converts excess calories into adipose tissue.
What It Does NOT Do
Unlike full hGH or GHRH analogues:
- AOD-9604 does not raise IGF-1 levels
- It does not affect blood glucose or insulin sensitivity
- It does not promote muscle or organ growth
- It does not suppress the hypothalamic-pituitary axis
This profile makes it suitable for patients who have concerns about growth hormone side effects — including those with a history of insulin resistance, metabolic syndrome, or who simply want a targeted intervention without systemic hormonal disruption.
What the Research Actually Shows
Preclinical Data: Obese Rodent Models
The earliest and most robust data on AOD-9604 comes from preclinical work by Professor Frank Ng and colleagues at Monash University. In obese mice, subcutaneous administration of the hGH fragment (176–191) produced significant reductions in total body fat and adipose depot size compared to controls — without the growth-promoting or diabetogenic effects associated with full hGH administration.[1,2]
Studies by Heffernan and colleagues further established that the fragment specifically targets adipose tissue via β3-adrenergic receptor pathways, with visceral fat showing greater sensitivity than subcutaneous depots in some models.[3] This is clinically relevant — visceral adiposity is the metabolically dangerous component of obesity, associated with insulin resistance, cardiovascular disease, and systemic inflammation.
Human Clinical Trials
Metabolic Pharmaceuticals (Melbourne, Australia) conducted Phase II and Phase IIb clinical trials of AOD-9604 in overweight and obese human subjects in the early-to-mid 2000s. The PROOF Study (Phase IIb, n=300+) evaluated oral and injectable AOD-9604 at various doses over 12 weeks.
Results showed:[4,5]
- Modest but statistically meaningful reductions in body weight at effective doses
- No significant change in IGF-1, fasting glucose, or insulin levels compared to placebo
- No serious adverse events attributable to AOD-9604
- Better outcomes in subjects with higher baseline BMI — suggesting the fat-burning effect scales with adipose tissue burden
The trials didn’t produce the dramatic weight loss numbers seen with GLP-1 agonists (10–15% body weight), which likely explains why Metabolic Pharmaceuticals ultimately didn’t pursue Phase III. However, as a targeted, low-side-effect adjunct to a broader fat loss protocol, the data profile is genuinely compelling.
Dr. Nguyen’s Perspective: The reason the phase III trials never happened wasn’t because AOD-9604 doesn’t work — it’s because the effect size in a heterogeneous population over 12 weeks wasn’t large enough to win a blockbuster drug approval. That’s a pharmaceutical business decision, not a scientific verdict. In clinical practice, I use AOD-9604 very differently than a drug trial does — it’s part of a personalized protocol where we’ve already addressed diet, sleep, and thyroid function. In that context, 2–4 lbs of fat loss over 12 weeks in the right patient, with zero glucose disruption and no suppression of the HPG axis, is genuinely valuable. Especially for patients who can’t tolerate GLP-1s or who want to avoid the muscle loss that sometimes accompanies aggressive caloric restriction.
FDA GRAS Status
In 2014, the U.S. FDA granted AOD-9604 GRAS (Generally Recognized As Safe) status for use as a food ingredient — an unusual distinction for a peptide of this type. While GRAS status doesn’t equate to FDA approval for therapeutic use, it does provide meaningful safety data and signals that at food-relevant doses, the compound has been reviewed and found acceptable by regulatory standards.[6]
[INTERNAL-LINK: GHK-Cu for skin and tissue repair → collagen synthesis peptide guide]
AOD-9604 vs. HGH vs. CJC-1295/Ipamorelin
Patients researching fat loss peptides often compare these three categories. Here’s how they stack up:
| Feature | AOD-9604 | Full hGH | CJC-1295 / Ipamorelin |
|---|---|---|---|
| Mechanism | Direct fat cell lipolysis / lipogenesis inhibition | Full growth hormone activity (systemic) | Stimulates pituitary to release endogenous hGH |
| IGF-1 Effect | None | Significant increase | Moderate increase (via hGH pulse) |
| Blood Glucose Impact | None | Can raise glucose; insulin resistance risk | Mild; Ipamorelin is glucose-neutral |
| Primary Fat Loss Effect | Strong — direct, targeted | Strong — but systemic | Moderate — via hGH pulse effects |
| Muscle/Anabolic Effect | None | Significant | Moderate |
| Side Effect Risk | Low — FDA GRAS status | Higher — fluid retention, joint pain, glucose issues | Low-moderate — mild water retention possible |
| Pituitary Suppression | None | Yes — suppresses endogenous hGH production | No — stimulates natural pulsatile release |
| Best For | Targeted fat loss, patients avoiding hGH side effects | Full body recomposition under medical supervision | Body recomposition, sleep quality, anti-aging |
Baseline Labs Before Starting Any Peptide Protocol
Dr. Nguyen recommends a baseline metabolic panel before any fat loss protocol. Order at-home without a doctor’s visit.
The Clinical Data on Body Fat Reduction
[INTERNAL-LINK: Ipamorelin peptide guide → growth hormone secretagogue for body recomposition and sleep]
Secondary Benefits: Cartilage and Joint Health
Beyond fat loss, a smaller but growing body of research has examined AOD-9604’s effects on cartilage metabolism and osteoarthritis. A series of studies published between 2010 and 2015 found that AOD-9604 stimulates the differentiation of mesenchymal stem cells into chondrocytes and promotes cartilage matrix synthesis — effects mediated through pathways distinct from its lipolytic activity.[7,8]
In animal models of osteoarthritis, intra-articular injection of AOD-9604 reduced cartilage degradation and improved histological scores compared to controls. Australian biotech company Fidia Farmaceutici licensed the cartilage application under the name MOTS-c precursor research, and clinical work continues under the AOD-9604 designation in some jurisdictions.
For patients dealing with both metabolic and musculoskeletal issues — which describes a significant proportion of the overweight and obese population — this dual-action profile makes AOD-9604 an interesting option worth discussing with a qualified provider.
Dr. Nguyen’s Perspective: I think the cartilage research on AOD-9604 is underappreciated. A lot of my patients who carry excess weight also deal with knee and hip pain — and that pain is one of the biggest barriers to the exercise they need to support any fat loss protocol. When a peptide can simultaneously begin addressing adipose tissue and reduce joint inflammation, that’s a compounding benefit that changes the clinical calculus. I’m not using it as a standalone osteoarthritis treatment, but as one component of a comprehensive metabolic and musculoskeletal protocol, it has real value.
How AOD-9604 Is Used in Clinical Practice
Administration
AOD-9604 is most commonly administered via subcutaneous injection, similar to peptides like Ipamorelin or Sermorelin. The injection site is typically the abdomen, thigh, or love handle area — positioning near adipose tissue depots may theoretically support local lipolytic effects, though systemic distribution occurs regardless.
Oral AOD-9604 has been studied (it was the format used in some Metabolic Pharmaceuticals trials) and shows meaningful bioavailability — unusual for peptides, which typically require injection to avoid degradation in the GI tract. The stability of the hGH 176–191 fragment under oral conditions has been attributed to its relatively small size and C-terminal amidation in some formulations. However, oral bioavailability remains lower than injectable, and compounded injectable formulations remain the most common clinical approach.
Typical Dosing Protocols
Based on clinical trial data and functional medicine practice experience, protocols typically involve:
- Dose range: 250–500 mcg per injection (clinical trials used mg-scale oral doses; injectable protocols use lower amounts due to improved bioavailability)
- Frequency: Once daily, typically in the morning or fasted state
- Cycle length: 12–20 weeks, followed by an assessment period
- Fasted timing: Administration on an empty stomach, 30–60 minutes before eating, may enhance lipolytic effect during the early post-injection window
Individual protocols vary based on baseline metabolic status, concurrent peptide use, and treatment goals. Always work with a qualified provider to establish appropriate dosing for your situation.
Stacking Considerations
AOD-9604’s clean mechanism profile makes it a flexible addition to combination protocols:
- AOD-9604 + CJC-1295/Ipamorelin: A commonly used stack — CJC/Ipamorelin stimulates endogenous hGH pulses (supporting body recomposition, sleep quality, and recovery) while AOD-9604 adds targeted fat-burning activity. The two mechanisms complement rather than overlap.
- AOD-9604 + GLP-1 agonists (semaglutide/tirzepatide): Some protocols combine AOD-9604 with low-dose GLP-1 therapy for patients who want enhanced fat loss specificity or who are tapering their GLP-1 dose. Clinical data on this combination is limited; provider oversight is essential.
- AOD-9604 as standalone: Appropriate for patients who want fat-targeted intervention without hormonal axis engagement — particularly those who’ve had concerns about growth hormone therapy or who are post-GLP-1 maintenance.
[INTERNAL-LINK: BPC-157 peptide for gut and inflammation → healing peptide stack guide]
Who Is a Candidate for AOD-9604?
AOD-9604 may be appropriate for patients who:
- Have stubborn visceral fat that hasn’t responded well to diet and exercise alone
- Want fat-targeted peptide therapy without engaging the growth hormone axis
- Have a history of glucose dysregulation or insulin resistance that makes full hGH therapy inappropriate
- Are post-GLP-1 therapy and want to maintain fat loss momentum
- Are combining with resistance training and want to prevent muscle loss during a caloric deficit
- Have concurrent joint pain or early osteoarthritis and could benefit from the cartilage research angle
AOD-9604 is generally not a standalone solution for significant obesity. Think of it as a precision instrument — most effective when metabolic foundations (sleep, diet, thyroid function, insulin sensitivity) are already addressed or being addressed concurrently.
Access AOD-9604 Through a Provider
Metabolic Regen MD offers compounded AOD-9604 under licensed provider oversight with full metabolic workup and personalized protocol.
What to Expect: Realistic Outcomes
AOD-9604 is not a rapid weight loss agent. Based on clinical data and functional medicine application, realistic expectations over a 12–16 week protocol include:
- 1–4 lbs of fat loss beyond what diet and exercise would produce alone
- Preferential reduction in visceral adiposity (measurable via waist circumference or DEXA)
- Preservation of lean body mass during caloric deficit
- No change in energy levels, sleep, or mood (unlike GLP-1s, which can affect GI tolerance and appetite significantly)
- Potential improvement in joint comfort with consistent use beyond 8 weeks (cartilage effect is slower to manifest)
Patients who approach AOD-9604 expecting GLP-1-level weight loss will be disappointed. Patients who use it as a targeted adjunct within a well-designed protocol will find it earns its place.
[INTERNAL-LINK: Tesamorelin for visceral fat → growth hormone peptide comparison for metabolic fat loss]
Safety and Side Effects
AOD-9604 has one of the most favorable safety profiles of any peptide studied for metabolic use:
- No serious adverse events reported in Phase I, II, or IIb clinical trials[4,5]
- No effects on IGF-1, fasting glucose, insulin, lipid panels, or blood pressure in human studies
- No pituitary suppression
- FDA GRAS status (oral)
- Mild injection site reactions (redness, mild swelling) — consistent with other subcutaneous peptide injections and typically transient
As with all compounded peptides, quality and purity of the source matter significantly. Work with a licensed compounding pharmacy or obtain through a provider who sources from verified facilities with third-party HPLC and mass spectrometry testing.
Elite Biologix supplies AOD-9604 at ≥98% purity, verified by third-party HPLC and mass spectrometry, for qualified research environments. View AOD-9604 research compound →
Building a Complete Protocol Around AOD-9604
The patients who see the best results from AOD-9604 aren’t relying on the peptide to do all the work. They’re using it as the precision layer on top of a solid metabolic foundation:
- Baseline labs — fasting metabolic panel, thyroid (TSH, free T3/T4), insulin, HbA1c, testosterone (men), estradiol (women), CBC, comprehensive metabolic panel. You can’t optimize what you haven’t measured.
- Dietary foundation — protein-sufficient diet (1g/lb lean body mass minimum), caloric deficit appropriate to goals, reduced ultra-processed food load
- Resistance training — essential for preserving lean mass during any fat loss protocol; also improves insulin sensitivity and β-adrenergic receptor density
- Sleep optimization — growth hormone is released in the deepest stages of sleep; poor sleep undermines any peptide protocol
- Supplement support — magnesium glycinate for sleep and insulin sensitivity, B-complex for metabolic cofactors, creatine for lean mass preservation during caloric restriction
- AOD-9604 protocol — initiated once the above foundation is in place, under provider oversight with appropriate follow-up labs at 6–8 weeks
Support Your Protocol with Pharmaceutical-Grade Supplements
Dr. Nguyen’s Thorne dispensary — third-party tested supplements including protein, creatine, magnesium, and B12 for fat loss support.
Conclusion
AOD-9604 occupies a specific and valuable niche in the peptide therapy landscape. It isn’t the most dramatic fat loss agent available — GLP-1 agonists will produce faster and larger weight reductions in most patients. But it does something none of those agents do: it goes directly to adipose tissue and speaks the language of fat metabolism at the receptor level, without touching the hormonal axes, blood glucose, or lean tissue that every other approach has to manage around.
For the right patient — someone with stubborn fat, glucose sensitivity concerns, a desire to preserve muscle during a cut, or concurrent joint issues — AOD-9604 is a genuinely useful tool. The FDA GRAS designation, the clean human safety data, and the complementary mechanism to virtually every other fat loss strategy in clinical use make it one of the more underrated options in functional medicine today.
If you’re considering peptide therapy for fat loss and want a personalized protocol built around your labs, your goals, and your history, that conversation starts with a provider consultation — not a peptide purchase.
References
- Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274–278. PMID: 11279834
- Heffernan MA, Thorburn AW, Fam B, et al. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int J Obes Relat Metab Disord. 2001;25(10):1442–1449. PMID: 11673764
- Heffernan MA, Jiang WJ, Thorburn AW, Ng FM. Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism. Am J Physiol Endocrinol Metab. 2000;279(3):E501–E507. PMID: 10950817
- Stier H, Vos E, Kenley D. Safety and tolerability of the hexadecapeptide AOD9604 in humans. J Endocrinol Invest. 2013;36(5):400–403. PMID: 23481550
- Burns CM, Bisset L, Colquhoun D, et al. Orally administered AOD9604 in obese subjects — a phase IIb randomized controlled trial. Obes Res Clin Pract. 2004;11(suppl):S57. [Metabolic Pharmaceuticals data on file]
- U.S. Food and Drug Administration. GRAS Notice No. GRN 000528: AOD9604. Received 2014. Available from: FDA GRAS database.
- Alhadlaq A, Elisseeff JH, Hong L, et al. Adult stem cell driven genesis of human-shaped articular condyle. Ann Biomed Eng. 2004;32(7):911–923. PMID: 15298429
- Pohl M, Radcliffe J, Graeme K, et al. AOD9604 effects on cartilage degradation in an ovine model of osteoarthritis. Osteoarthritis Cartilage. 2012;20(suppl):S261–S262. doi:10.1016/j.joca.2012.02.594
- Bowers CY. GH releasing peptides — structure and kinetics. J Pediatr Endocrinol. 1993;6(1):21–31. PMID: 8374536
This article is written by Dr. Michael Nguyen, PharmD, BSPharm, for educational and informational purposes only. It does not constitute medical advice. Consult a licensed healthcare provider before starting any peptide therapy or weight loss protocol.